Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLITTER: Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients
NCT03640026Phase 4Terminated
- Sponsor
- CHD Vendée
- Start
- Mar 2019
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus + Wuzhi capsule in transplant rejection, sponsored by CHD Vendée. Primary endpoint: Proportion of haemodialysis patients modifying their glycemic profile receiving Tacrolimus at 14 days. Started Mar 2019; status: terminated.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
transplant rejection
Beyond the preview
Go deeper on NCT03640026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03640026.